We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current MDNAF market cap is 126.16M. The company's latest EPS is CAD -0.3310 and P/E is -6.71.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.25M | -17.4M | -22.47M | -16.3M | -18.67M |
| Net Income | -8.28M | -17.29M | -22.58M | -10.05M | -25.47M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 38M | 42.25M | 23.46M | 36.45M | 19.13M |
| Total Liabilities | 1.85M | 4.11M | 2.62M | 6.96M | 13.94M |
| Total Equity | 36.15M | 38.15M | 20.84M | 29.49M | 5.19M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -8.95M | -15.31M | -23.58M | -12.66M | -16.26M |
| Investing | -15M | 5.01M | 10.05M | N/A | N/A |
| Financing | 44.28M | 18.26M | 3.88M | 24.76M | N/A |
| Market Cap | 126.16M |
| Price to Earnings Ratio | -6.71 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 10.05 |
| Price to Book Ratio | 32.9 |
| Dividend Yield | - |
| Shares Outstanding | 76.93M |
| Average Volume (1 week) | 130.7k |
| Average Volume (1 Month) | 75.5k |
| 52 Week Change | 900.00% |
| 52 Week High | 2.20 |
| 52 Week Low | 0.158 |
| Spread (Intraday) | 0.15 (8.52%) |
| Company Name | Medicenna Therapeutics Corporation (QB) |
| Address |
200 - 1920 yonge street toronto, ontario M4S 3E2 |
| Website | https://www.medicenna.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
